NDC product
Blujepa
NDC 0173-0922 · GlaxoSmithKline LLC
Key facts
| Product NDC | 0173-0922 |
|---|---|
| Proprietary name | Blujepa |
| Nonproprietary name | gepotidacin |
| Substances | GEPOTIDACIN MESYLATE |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | GlaxoSmithKline LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA218230 |
| Pharmacologic classes | Cholinesterase Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Topoisomerase 2 Inhibitors [MoA], Topoisomerase 4 Inhibitors [MoA], Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor [EPC] |
| Marketing start | Mar 25, 2025 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: